Uniphar EBITDA per Share
The EBITDA per Share of Uniphar (UPR.IR) as of Aug 5, 2026 is 0.35 EUR.
Get this data via API
Financial Data API
EBITDA per Share
0.35EUR
Last updated:
EBITDA per Share of Uniphar is 2026 0.35 EUR. EBITDA per Share of Uniphar was 2025 0.00 EUR. It decreases by % higher compared to the previous year.
Access this data via the Eulerpool API
Uniphar Stock analysis
What does Uniphar do? Uniphar PLC is an Irish company that was founded in 1994 and operates in the healthcare industry. The company is headquartered in Dublin and employs over 2,500 people worldwide.
The history of Uniphar began as a pharmacy distribution company that supplied medications to retailers and healthcare facilities. Over the years, however, the company has expanded its business model and now offers a wide range of healthcare products and services.
Uniphar's business model encompasses three main areas: Healthcare Services, Commercial & Clinical Supply Chain, and Product Access & Specialty Medicines. In the Healthcare Services area, Uniphar provides consulting services, training, and leadership coaching for healthcare facilities. The Commercial & Clinical Supply Chain division includes the storage, logistics, and distribution of medications, as well as the clinical care of patients. The Product Access & Specialty Medicines division focuses on access to medications with high medical demand and rare diseases.
Uniphar also offers a wide range of healthcare products, including generics, branded medications, and medical devices. The company has partnerships with leading pharmaceutical companies such as Pfizer, Eli Lilly, and Merck.
In recent years, Uniphar has also made several significant acquisitions to expand and diversify its business. In 2018, the company acquired UK-based pharmaceutical distributor Cahill May Roberts, and in 2019, the acquisition of Durbin, an international supplier of clinical supply products, was completed.
Uniphar is committed to improving healthcare in Ireland and worldwide and offers a wide range of products and services to achieve this goal. The company has earned a reputation as a reliable partner for healthcare facilities and pharmaceutical companies and is on a steady growth trajectory. Uniphar is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Uniphar stock
EBITDA per Share of Uniphar is 0.35 EUR in 2026.
On Eulerpool you can find the complete historical development of EBITDA per Share Uniphar since 2006 – with annual values, charts, and detailed analysis.
EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.
Access this data via the Eulerpool API
Income Statement — Uniphar
All Key Metrics — Uniphar
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth